Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Impact · against what's priced in

Allarity Therapeutics secures critical non-dilutive capital to extend its operational runway into 2028, significantly reducing near-term insolvency risk. This financing allows the company to focus on Phase 2 enrollment and FDA preparation for stenoparib without the immediate pressure of equity dilution.

ALLR+0.60

No priced-in read yet